Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Closing the Gap in Care in Seronegative Inflammatory Arthritis (Metrix II)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2013 by Pope Research Corporation.
Recruitment status was:  Recruiting
Sponsor:
Collaborators:
Academic Medical Organization of Southwestern Ontario
CIORA
Abbott
Information provided by (Responsible Party):
Pope Research Corporation
ClinicalTrials.gov Identifier:
NCT01749618
First received: November 6, 2012
Last updated: May 21, 2013
Last verified: May 2013
  Purpose
Rheumatologists treating patients with seronegative arthritis will be randomized to treat their patients to a target or to treat their patients under their usual standard of care. All physicians will perform an initial chart audit. Following the initial chart audit, all physicians in the treat-to-target group will receive accredited educational training. Six months after the initial chart audit, all physicians will perform a repeat audit to see if patients are assessed more systematically and treated to a target of low disease state.

Condition Intervention
SpA
PsA
Behavioral: Education and Feedback

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Closing the Gap in Care in Seronegative Inflammatory Arthritis: From Identification to Implementation of Treating to Target: A Randomized Trial of Feedback, Education, and Behavioural Change

Resource links provided by NLM:


Further study details as provided by Pope Research Corporation:

Primary Outcome Measures:
  • Improvement of Systematic Assessments [ Time Frame: November 2012 - November 2013 ] [ Designated as safety issue: No ]
    Physicians in the Education and Feedback arm are assessed via a needs assessment to identify the care gaps for their patients with inflammatory arthritis. After the education and feedback, they complete a second chart audit and their improvements in assessments is recorded.


Estimated Enrollment: 40
Study Start Date: November 2012
Estimated Study Completion Date: November 2013
Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: No education or feedback
Rheumatologists randomized to this treatment arm receive no additional education or feedback about their systematic assessments of patients
Experimental: Education and Feedback
Rheumatologists randomized to receive education and feedback participate in six web conferences designed to improve their systematic assessments of their patients, and are given feedback about their performances
Behavioral: Education and Feedback
Rheumatologists are rated on how systematically they assess their patients, and receive six sessions of university accredited education about systematic assessments of patients with seronegative arthritis.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Canadian Rheumatologist

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01749618

Locations
Canada, Ontario
Dr. Vandana Ahluwalia
Brampton, Ontario, Canada
Dr. Sanjay Dixit
Burlington, Ontario, Canada, L7L 0B7
Dr Pauline Boulos
Hamilton, Ontario, Canada, L8N 1Y2
Dr. Nikhil Chopra
London, Ontario, Canada, N6B 2E8
Dr Angela Montgomery
Mississauga, Ontario, Canada, L5B 2P7
Credit Valley Rheumatology
Mississauga, Ontario, Canada, L5M 2V8
The Medical Centre
Peterborough, Ontario, Canada, K9J 7B3
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Dr. Arthur Karasik
Toronto, Ontario, Canada, M9C 5N2
Sponsors and Collaborators
Pope Research Corporation
Academic Medical Organization of Southwestern Ontario
CIORA
Abbott
Investigators
Principal Investigator: Janet E Pope, MD, MPH, FRCPC Pope Research Corp., St. Joseph's Health Care, Western University
  More Information

Responsible Party: Pope Research Corporation
ClinicalTrials.gov Identifier: NCT01749618     History of Changes
Other Study ID Numbers: Metrix II 
Study First Received: November 6, 2012
Last Updated: May 21, 2013
Health Authority: Canada: Health Canada

Keywords provided by Pope Research Corporation:
Seronegative Inflammatory Arthritis
SpA
PsA
Randomized
Behavioural Change

Additional relevant MeSH terms:
Arthritis
Joint Diseases
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on December 09, 2016